NCT07615907Not yet recruiting
A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
Sodium Propionate Combined With Anti-PD-1 Immunotherapy on Tumor Efficacy in Gastric Cancer Patients
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 30 May 2026
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Jinling Hospital, China
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07615907
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 30 May 2026 to the primary completion date, 30 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent primary malignant tumors at other sites;
Other illness
- Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;
- Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;
- Patients with mental disorders, consciousness disturbance, or poor treatment compliance;
- Suspected or confirmed history of drug abuse;
Other
- Immunodeficiency, or long-term use of immunosuppressants and glucocorticoids;
- Pregnant or lactating women;
- Sponsors, investigators directly involved in this trial, and their immediate family members;
- Individuals unsuitable for enrollment for any reason as judged by the investigator.
Who the study is looking for
- Subjects voluntarily participated in the trial and signed the informed consent form;
- Aged ≥ 18 years and \< 80 years, regardless of gender;
- Stable vital signs;
- Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;
- Tumors judged as unresectable by attending physicians;
- Receiving anti-PD-1 therapy combined with chemotherapy as first-line treatment;
- No history of allergic diseases and non-allergic constitution;
- No history of drug abuse;
- Non-pregnant and non-lactating females (applicable to male subjects as well);
- No participation in any drug clinical trial (including investigational drugs of this trial) within 3 months prior to enrollment.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xinying Wang Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.